Product Description
A cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Lisata Therapeutics, Inc.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Type 1 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02691247 |
CLBS03-P01 | P2 |
Completed |
Type 1 Diabetes |
2019-03-01 |
27% |
2022-09-24 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/11/2022 |
News Article |
Regulatory T-Cell Therapies Market, 2035 |
|
01/10/2022 |
News Article |
Regulatory T-Cell Therapies Market by Target Indications, Key Players and Key Geographies - Global Industry Trends and Forecasts, 2021-2035 - ResearchAndMarkets.com |
|
09/10/2021 |
News Article |
Novel T-Cell Immunotherapies Market Trends and Global Forecasts, 2021-2030 |
|
09/10/2021 |
News Article |
Novel T-Cell Immunotherapies Market, 2030 |